Skip to main content

Table 1 Clinical characteristics of non-relapsing and relapsing VL patients

From: High levels of anti-Leishmania IgG3 and low CD4+ T cells count were associated with relapses in visceral leishmaniasis

 

Patient

Comorbidities

Active phase treatment

Cumulative Amph B dose

in VL active phase

Previous episodes of VL

Time between first VL episode and current active phase

Relapse during follow-up

Time between current active phase and relapse

Total number of VL episodes

Total follow-up

Non-Relapsing

VL01

Smoker

Previous marijuana use

Occasional use of alcohol

Amph. B deoxychol 50 mg/day per 12 days followed by Liposomal Amph. B 20 mg/kg

28.5 mg/kg

No

NA

No

NA

1

12 months

VL02

No information

Liposomal Amph. B 20 mg/kg

20 mg/kg

No

NA

No

NA

1

12 months

VL03

Occasional use of alcohol

Positive serology for Chagas Disease

Amph. B deoxychol 50 mg/day per 3 days followed by Liposomal Amph. B 20 mg/kg

21.7 mg/kg

No

NA

No

NA

1

12 months

VL04

Virchowian

hanseniasis

ADHD

Development delay – infantilized behavior

Amph. B deoxychol 50 mg/day per 4 days followed by Liposomal Amph. B 20 mg/kg

22 mg/kg

No

NA

No

NA

1

12 months

VL05

Dyslipidemia

Past of drug addiction

Amph. B deoxychol - 1000 mga

 

No

NA

No

NA

1

Post-treatment

VL08

Arterial hypertension

Smoker

Alcoholic

Amph. B Lipid Complex 20 mg/kg

20 mg/kg

No

NA

No

NA

1

12 months

VL11

Alcoholic

Ex-smoker

Past of schistosomiasis and gonorrhea

Amph. B Lipid Complex 200 mg/day for 4 days followed by Liposomal Amph. B 20 mg/kg (in 7 weeks)

20 mg/kg

No

NA

No

NA

1

6 months

VL12

Drug addicted

Amph. B deoxychol 150 mg followed by Liposomal Amph. B 20 mg/kg

23 mg/kg

No

NA

No

NA

1

6 months

VL13

Alcoholic

Smoker

Meglumine antimoniate 20 mgSb+ 5/Kg/day for 3 days followed by Liposomal Amph. B 20 mg/kg

20 mg/kg

No

NA

No

NA

1

Post-treatment

VL14

Arterial hypertension

Ex-smoker

Liposomal Amph. B 20 mg/kg in7 days

20 mg/kg

No

NA

No

NA

1

Post-treatment

Relapsing

VL06

Arterial hypertension

Diabetes mellitus type 2

Metabolic syndrome

Amph. B Lipid Complex 20 mg/kg

20 mg/kg

Yes (1)

4 months

No

NA

2

12 months

VL07

Occasional use of alcohol

Amph. B Lipid Complex 40 mg/kg

40 mg/kg

Yes (3)

15 months

Yes

Jan, 2019

4 months

5

12 months

VL09

Chronic renal disease

Hypersplenim

Past of schistosomiasis

Amph. B Lipid Complex 20 mg/kg

20 mg/kg

Yes (2)

15 months

Yes

Oct, 2019

12 months

4

12 months

VL10

Chagasic cardiac insufficiency

Amph. B Lipid Complex 25 mg/kg

25 mg/kg

No

NA

Yes

Feb, 2019

4 months

2

6 months

VL15

Ex-smoker

Pulmonary hypertension

Subclinic hypothyroidism

Liposomal Amph. B 40 mg/kg

40 mg/kg

Yes (2)

5 months

No

NA

3

Post-treatment

  1. VL visceral leishmaniasis, yo years old, ADHD attention deficit hyperactivity disorder, Amph. B deoxychol Amphotericin B deoxycholate, Liposomal Amph. B Liposomal amphotericin B, Amph. B Lipid Complex Amphotericin B lipid complex
  2. ano exact dose information available NA not applicable